Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vecuronium bromide
Drug ID BADD_D02341
Description Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.
Indications and Usage Vecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.
Marketing Status Prescription; Discontinued
ATC Code M03AC03
DrugBank ID DB01339
KEGG ID D00767
MeSH ID D014673
PubChem ID 39764
TTD Drug ID D0Z8HG
NDC Product Code 0409-1632; 55150-235; 10695-021; 0703-2914; 67457-475; 60870-0297; 60722-1008; 68083-139; 55486-1566; 63323-781; 63323-782; 55150-236; 47335-932; 0409-1634; 0703-2925; 0143-9234; 53183-1308; 0143-9232; 67457-438; 68083-140; 51662-1475; 47335-931
Synonyms Vecuronium Bromide | Bromide, Vecuronium | Vecuronium Hydrobromide | Hydrobromide, Vecuronium | Norcuron | Vecuronium | Vecuronium Phosphate | Phosphate, Vecuronium | Vecuronium Citrate | Citrate, Vecuronium | Vecuronium Hydrochloride | Hydrochloride, Vecuronium | Vecuronium Maleate | Maleate, Vecuronium | NC-45 | NC 45 | NC45 | ORG-NC45 | ORG NC45 | ORG-NC 45 | ORG NC 45 | ORGNC 45 | ORG-NC-45 | ORGNC45 | Vecuronium Bromide, Quaternary Ion
Chemical Information
Molecular Formula C34H57BrN2O4
CAS Registry Number 50700-72-6
SMILES CC(=O)OC1CC2CCC3C(C2(CC1N4CCCCC4)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Apnoea22.02.01.001--
Bronchospasm10.01.03.012; 22.03.01.004--
Delayed recovery from anaesthesia17.02.04.011; 12.02.12.003--Not Available
Dermatitis23.03.04.002--Not Available
Drug ineffective08.06.01.006--Not Available
Erythema23.03.06.001--Not Available
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.004--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscular weakness15.05.06.001; 17.05.03.005--
Myopathy15.05.05.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Neuromuscular block prolonged17.05.04.005; 12.02.12.004--Not Available
Paralysis17.01.04.004--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.003--Not Available
Respiratory depression22.02.01.010; 17.02.05.047--Not Available
Respiratory failure14.01.04.003; 22.02.06.002--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Tachycardia02.03.02.007--Not Available
Therapeutic response increased08.06.01.021--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages